Newsroom

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Victory Capital Holdings, Inc. (NASDAQ: VCTR) and First Eagle Investments.Halper Sadeh encourages Victory Capital shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.The investigation concerns whether Victory Capital and its board of directors viol...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Max Buffer UCITS ETF - September 25.08.2026 MSEP.LN IE0009DRFET8   50,002.00 USD   1,410,507.36   28.209  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - June 25.08.2026 QJUN.LN IE000HFBJ0U0 4,550,002.00 USD 101,778,393.87   22.369  ...

TORONTO--(BUSINESS WIRE)--Una AI, an AI-powered FP&A platform, today announced that BPM Partners named it a 2026 Core Vendor with an "Outstanding" overall customer-satisfaction rating in its 2026 BPM Pulse research. Out of dozens of vendors in the financial planning and analysis (FP&A) software space, Una AI is among 14 covered in BPM Partners' 2026–2027 Vendor Landscape Matrix. Core Vendors are selected by the vendor-neutral advisory firm based on functionality, market success, and cus...

BOSTON--(BUSINESS WIRE)--For years, the media and entertainment industry has hesitated to use AI-voiced dubbing due to concern for audience experience. New data from 3Play Media, a global leader in video accessibility and localization, shows that audiences are already engaged with AI-dubbing on a massive scale on YouTube. “Our dubs have had over 30 million hours watched on YouTube,” said Erik Ducker, VP of Product Growth at 3Play Media. “The data shows that audiences are choosing and engaging w...

NEW YORK--(BUSINESS WIRE)--Jadian Capital ("Jadian"), an investment firm focused on alternative real estate and asset-intensive businesses, today announced that JIOS, its leading vertically integrated industrial outdoor storage ("IOS") platform, has secured a $277 million loan from affiliates of Apollo Global Management, Inc. (NYSE: APO) for a 37-property IOS portfolio spanning 23 markets. The portfolio is concentrated in infill locations near key logistics hubs and dense population nodes with...

San Carlos, Califórnia--(BUSINESS WIRE)--A BeOne Medicines Ltd.(Nasdaq: ONC; HKEX: 06160; SSE: 688235), empresa global de oncologia, anunciou hoje que a Food and Drug Administration (FDA) dos EUA aprovou o pedido suplementar de licença biológica (sBLA) para TEVIMBRA®(tislelizumab) em combinação com ZIIHERA®(zanidatamab) e quimioterapia para o tratamento de primeira linha de pacientes adultos com adenocarcinoma gástrico, da junção gastroesofágica ou esofágico (GEA) HER2-positivo (HER2+) localmen...

加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- 全球性腫瘤公司BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235)今日宣布，美國食品藥物管理局(FDA)已核准TEVIMBRA® (tislelizumab)聯合ZIIHERA® (zanidatamab)及化療，用於不可切除局部晚期或轉移性HER2陽性(HER2+)胃腺癌、胃食管結合部腺癌或食管腺癌(GEA)成人病患一線治療的補充生物製品授權申請(sBLA)。該核准以今年稍早發表於《新英格蘭醫學期刊》(The New England Journal of Medicine)的第三期HERIZON-GEA-01試驗結果為基礎。 GEA包括胃、胃食管結合部和食管的腺癌，在美國仍是存在重大未滿足醫療需求的領域，每年新診斷出超過31,000例胃癌病例。1約20%的GEA病患為HER2+疾病，這一亞型歷來難以治療。2,3,4 儘管近期取得了一些進展，但晚期或轉移性HER2+ GEA病患的長期預後仍充滿挑戰，對更有效的一線治療方案的需求十分迫切。在美國，存活...

米カリフォルニア州サンカルロス--(BUSINESS WIRE)--（ビジネスワイヤ） -- グローバルな腫瘍治療薬企業であるBeOne Medicines（ナスダック：ONC、香港証券取引所：06160、上海証券取引所：688235）は、米国食品医薬品局（FDA）が、切除不能な局所進行性または転移性のHER2陽性（HER2+）胃がん、胃食道接合部がん、または食道腺がん（GEA）の成人患者に対する一次治療として、TEVIMBRA®（ティスレリズマブ）とZIIHERA®（ザニダタマブ）および化学療法との併用療法に関する生物製剤承認申請（sBLA）を承認したことを発表しました。今回の承認は、今年初めにThe New England Journal of Medicine（ザ・ニューイングランド・ジャーナル・オブ・メディシン）誌に掲載されたHERIZON-GEA-01第3相試験の結果に基づいています。 胃、胃食道接合部、食道の腺がんを含む胃食道腺がん（GEA）は、米国において依然として大きなアンメットニーズのある分野であり、毎年3万1000件以上の胃がんの新規症例が診断されています1。GE...

SAN CARLOS, Kalifornien--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologieunternehmen, gab heute bekannt, dass die US-amerikanische Food and Drug Administration (FDA) den ergänzenden Antrag auf Zulassung eines biologischen Präparats (sBLA) für TEVIMBRA® (Tislelizumab) in Kombination mit ZIIHERA® (Zanidatamab) und einer Chemotherapie zur Erstlinienbehandlung erwachsener Patienten mit inoperablem, lokal fortgeschrittenem oder metastasier...